Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α

Kidney International

Volumn 84, Issue 3, 2013, Pages 545-554

  Matoba, Keiichiro ^a   Kawanami, Daiji ^a   Okada, Rina ^a   Tsukamoto, Masami ^a   Kinoshita, Jun ^a   Ito, Tomoko ^a   Ishizawa, Sho ^a   Kanazawa, Yasushi ^a   Yokota, Tamotsu ^a   Murai, Noriyuki ^a   Matsufuji, Senya ^a   Takahashi Fujigasaki, Junko ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cell signaling; diabetic glomerulosclerosis; diabetic nephropathy; hypoxia

Indexed keywords

ALBUMIN; FASUDIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHO KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION; GLOMERULOSCLEROSIS; HYPOXIA; IN VITRO STUDY; KIDNEY CORTEX; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; MALE; MESANGIUM CELL; MOLECULAR INTERACTION; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RENAL PROTECTION; SCLEROSIS; SIGNAL TRANSDUCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ALBUMINURIA; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; FIBROSIS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; KIDNEY CORTEX; MALE; MICE; MICE, MUTANT STRAINS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 84883458932     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.130     Document Type: Article

References (44)

1. Molitch ME, DeFronzo RA, Franz MJ et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79-S83.
2. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58: 2351-2366.
3. Manotham K, Tanaka T, Matsumoto M et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15: 1277-1288.
4. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872.
5. Palm F, Cederberg J, Hansell P et al. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003; 46: 1153-1160.
6. Ries M, Basseau F, Tyndal B et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging 2003; 17: 104-113.
7. Singh DK, Winocour P, Farrington K. Mechanisms of disease: The hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008; 4: 216-226.
8. Rosenberger C, Khamaisi M, Abassi Z et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008; 73: 34-42.
9. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70: 1469-1480.
10. Takiyama Y, Harumi T, Watanabe J et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: A possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 2011; 60: 981-992.
11. Isoe T, Makino Y, Mizumoto K et al. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int 2010; 78: 48-59.
12. Higgins DF, Kimura K, Bernhardt WM et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007; 117: 3810-3820.
13. Kamiyama M, Utsunomiya K, Taniguchi K et al. Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb 2003; 10: 117-123.
14. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
15. Kawanami D, Matoba K, Kanazawa Y et al. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-kappaB signaling pathway activation in vascular endothelial cells. Biochem Biophys Res Commun 2011; 411: 798-803.
16. Nishikimi T, Akimoto K, Wang X et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-1796.
17. Kanda T, Wakino S, Hayashi K et al. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009-2019.
18. Nagatoya K, Moriyama T, Kawada N et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684-1695.
19. Gojo A, Utsunomiya K, Taniguchi K et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 568: 242-247.
20. Matoba K, Kawanami D, Ishizawa S et al. Rho-kinase mediates TNF-alphainduced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun 2010; 402: 725-730.
21. Kolavennu V, Zeng L, Peng H et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-723.
22. Kikuchi Y, Yamada M, Imakiire T et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192: 595-603.
23. Wang W, Wang Y, Long J et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab 2012; 15: 186-200.
24. Turcotte S, Desrosiers RR, Beliveau R. HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 2003; 116: 2247-2260.
25. Hayashi M, Sakata M, Takeda T et al. Hypoxia up-regulates hypoxiainducible factor-1alpha expression through RhoA activation in trophoblast cells. J Clin Endocrinol Metab 2005; 90: 1712-1719.
26. Russo LM, Sandoval RM, Campos SB et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20: 489-494.
27. Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 1999; 94: 4177-4185.
28. Higgins DF, Biju MP, Akai Y et al. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 2004; 287: F1223-F1232.
29. Sochor M, Kunjara S, McLean P. Regulation of pathways of glucose metabolism in the kidney. The activity of the pentose phosphate pathway, glycolytic route and the regulation of phosphofructokinase in the kidney of lean and genetically obese (ob/ob) mice; comparison with effects of diabetes. Horm Metab Res 1988; 20: 676-681.
30. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005; 16(Suppl 1): S30-S33.
31. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS et al. Amelioration of longterm renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-3094.
32. Hiragushi K, Wada J, Eguchi J et al. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats. Kidney Int 2004; 65: 540-550.
33. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201.
34. Park JW, Park CH, Kim IJ et al. Rho kinase inhibition by fasudil attenuates cyclosporine-induced kidney injury. J Pharmacol Exp Ther 2011; 338: 271-279.
35. Takeda Y, Nishikimi T, Akimoto K et al. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res 2010; 33: 965-973.
36. Takata K, Morishige K, Takahashi T et al. Fasudil-induced hypoxiainducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008; 7: 1551-1561.
37. Epstein AC, Gleadle JM, McNeill LA et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
38. Li N, Yi F, Sundy CM et al. Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys. Am J Physiol Renal Physiol 2007; 292: F207-F216.
39. Schodel J, Klanke B, Weidemann A et al. HIF-prolyl hydroxylases in the rat kidney: Physiologic expression patterns and regulation in acute kidney injury. Am J Pathol 2009; 174: 1663-1674.
40. Berra E, Benizri E, Ginouves A et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22: 4082-4090.
41. Takeda K, Ho VC, Takeda H et al. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 2006; 26: 8336-8346.
42. McMahon S, Charbonneau M, Grandmont S et al. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281: 24171-24181.
43. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol 2009; 20: 1877-1887.
44. Shimokawa H, Seto M, Katsumata N et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999; 43: 1029-1039.